Can I qualify for financial assistance if I am currently covered by Medicare or other government insurance?

Yes, patients with Medicare and other government sponsored insurance can qualify for help from independent nonprofit foundations. JETREA CARE® can help refer qualifying patients to appropriate independent nonprofit foundations.

JETREA CARE® CO-PAY ASSISTANCE PROGRAM can help qualifying patients with commercial insurance pay no more than $25 for the cost of JETREA® that is not covered by their insurance, including co-pay or co-insurance, and/or deductible* – click here to find out more details.

JETREA CARE® can refer qualifying patients covered by Medicare or other government sponsored insurance to independent nonprofit foundations** which can offer co-pay assistance – click here to find out more details.

JETREA CARE® can help qualified uninsured patients to receive JETREA at no cost – click here to find out more details.

*JETREA CARE® CO-PAY ASSISTANCE PROGRAM does not apply to patient financial responsibility for the injection procedure. Co-pay assistance is capped at $2,000. Patients with any remaining balance will be referred to a nonprofit foundation.

**Independent nonprofit foundations provide assistance regardless of the choice of medicine, and decisions are based on financial need and according to criteria established by individual foundations. JETREA CARE® can assist patients by referring them to these independent nonprofit foundations. Neither ThromboGenics® nor JETREA CARE® can guarantee that patients will be eligible for or receive co-pay assistance after referral. Neither ThromboGenics® nor JETREA CARE® have controlling or managerial influence on these independent nonprofit foundations.

Qualifying patients will receive an approval letter for the JETREA CARE® CO-PAY ASSISTANCE PROGRAM or the JETREA CARE® Patient Assistance Program. Approval notification will also be sent to your doctor’s office.

Patients approved for the JETREA CARE® CO-PAY ASSISTANCE PROGRAM will be required to provide an explanation of benefits (EOB) verifying their financial responsibility (funds will be released upon submission).

Qualifying patients covered by Medicare or other government sponsored insurance and their doctors will be contacted directly by an appropriate independent nonprofit foundation with more information regarding their application, required documentation, and approval status.

Indication

JETREA (ocriplasmin) injection, for Intravitreal Injection, 1.25 mg/mL is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion.

Important Safety Information

Warnings and Precautions

A decrease of ≥ 3 lines of best-corrected visual acuity (BCVA) was experienced by 5.6% of patients treated with JETREA and 3.2% of patients treated with vehicle in the controlled trials. The majority of these decreases in vision were due to progression of the condition with traction and many required surgical intervention. Patients should be monitored appropriately.

Intravitreal injections are associated with intraocular inflammation/infection, intraocular hemorrhage and increased intraocular pressure (IOP). Patients should be monitored and instructed to report any symptoms without delay. In the controlled trials, intraocular inflammation occurred in 7.1% of patients injected with JETREA vs 3.7% of patients injected with vehicle. Most of the post-injection intraocular inflammation events were mild and transient. If the contralateral eye requires treatment with JETREA, it is not recommended within 7 days of the initial injection in order to monitor the post-injection course in the injected eye.

Potential for lens subluxation.

In the controlled trials, the incidence of retinal detachment was 0.9% in the JETREA group and 1.6% in the vehicle group, while the incidence of retinal tear (without detachment) was 1.1% in the JETREA group and 2.7% in the vehicle group. Most of these events occurred during or after vitrectomy in both groups.

Dyschromatopsia (generally described as yellowish vision) was reported in 2% of all patients injected with JETREA. In approximately half of these dyschromatopsia cases there were also electroretinographic (ERG) changes reported (a- and b-wave amplitude decrease).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088. You may also report side effects of JETREA online directly to ThromboGenics by clicking here if you are a Patient.

Disclaimer

The section of the Web site you selected contains information intended for US health care professionals only. Please certify that you are a US health care professional by clicking the appropriate link below or close out of this window to return to the home page.